-+ 0.00%
-+ 0.00%
-+ 0.00%

ASCENTAGE PHARMA ANNOUNCES GLOBAL REGISTRATIONAL PHASE III STUDY OF OLVEREMBATINIB IN FIRST-LINE TREATMENT OF PH+ ALL CLEARED BY US FDA AND EMA

Reuters·12/05/2025 00:00:00

Please log in to view news